Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …

Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Antisense technology is beginning to deliver on the broad promise of the technology. Ten
RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double …

This Perspective focuses on thiol-mediated uptake, that is, the entry of substrates into cells
enabled by oligochalcogenides or mimics, often disulfides, and inhibited by thiol-reactive …

Small interfering RNAs (siRNAs) are among the most promising therapeutic platforms in
many life-threatening diseases. Owing to the significant advances in siRNA design, many …

The PS modification enhances the nuclease stability and protein binding properties of
gapmer antisense oligonucleotides (ASOs) and is one of very few modifications that support …

Intracellular protein delivery is highly desirable for protein drug‐based cell therapy.
Established technologies suffer from poor cell‐specific cytosolic protein delivery, which …

Oligonucleotide phosphorothioates (OPS) are DNA or RNA mimics where one phosphate
oxygen is replaced by a sulfur atom. They have been shown to enter mammalian cells much …

ABSTRACT RNA-based therapeutics are emerging as a powerful platform for the treatment
of multiple diseases. Currently, the two main categories of nucleic acid therapeutics …

Oligonucleotide-based therapeutics have attracted attention as an emerging modality that
includes the modulation of genes and their binding proteins related to diseases, allowing us …